MSCL Satellos Bioscience Inc.

5.762USD8.240 CAD · TSX-3.06%Mkt Cap: 122.25M USDP/E: —

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company us…

Institutional holders12 on file

Key Statistics

Company
Market Cap122.25M USD
Enterprise Value98.74M USD
Revenue (TTM)—
Gross Profit-9.48M USD
Net Income (TTM)-24.87M USD
Revenue/Share—
Last Price5.762 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA80401L8033
Valuation
P/E (Trailing)—
P/E (Forward)-2.30
PEG—
EV/EBITDA-3.94
EV/Revenue—
P/S—
P/B3.27
EPS (TTM)-3.04 USD
EPS (Forward)-3.58 USD
52W Range
5.2876% of range13.27
52W High13.27 USD
52W Low5.287 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-89.52%
ROA-78.00%
ROIC—
ROCE-95.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.60M USD
CapEx (TTM)6.00K USD
FCF Margin—
FCF Yield-13.84%
Net Debt-61.84M USD
Net Debt/EBITDA1.73
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio11.22
Quick Ratio10.69
Book Value/Sh2.52 USD
Cash/Share2.92 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJan 30, 2026
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.35 USD
Upside (mean)+114.4%
Target Range11.19 USD – 13.29 USD
11.19+114.4% to mean13.29
# Analysts3
Ownership
Shares Out.21.22M
Float18.02M
Insiders6.37%
Institutions50.10%
Short Interest
Short Ratio1.2d
Short % Out.0.06%
Shares Short13.41K
Short (prev mo.)14.85K
Technical
SMA 507.542 (-23.6%)
SMA 2008.032 (-28.3%)
Beta1.19
S&P 52W Chg12.00%
Avg Vol (30d)12.72K
Avg Vol (10d)18.55K
Technical Indicators
RSI (14)33.5
MACD-0.4757
MACD Signal-0.4254
MACD Hist.-0.0503
BB Upper7.268 USD
BB Middle6.510 USD
BB Lower5.751 USD
BB Width23.30%
ATR (14)0.4100 USD
Vol Ratio (20d)1.07x

About Satellos Bioscience (TSE: MSCL)

›

Satellos Bioscience (TSE: MSCL) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.

The shares were at 8.240 CAD on 20 November 2026, down 7.2% over 52 weeks. Its 52-week range is 7.560 CAD to 18.98 CAD: the price is 56.6% below the high and 9.0% above the low.

Its market capitalisation is 174.82M CAD.

Satellos Bioscience reports return on equity of -89.5% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 61.84M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.67 CAD is 114.4% above the current price. The next earnings report is expected on 25 March 2027.